A Randomized Double-Blind Placebo-Controlled Study in Cat-Allergic Patients with Allergic Rhinitis Who Live with a Cat to Assess the Efficacy and Safety of Anti-Fel d 1 Antibodies during Natural Cat Exposure in the Home

Brief description of study

The main purpose of this study is to find out whether an experimental study drug called REGN1908-1909 works to reduce nasal and/or eye allergy symptoms and the need for allergy medicine use in patients with cat allergy who are currently living with a cat(s). In patients with cat allergy that also have asthma, this study will assess whether the study drug reduces asthma symptoms and improves breathing. The study drug has not been approved by the FDA and the aim of the study is to see how safe and effective the study drug is compared to placebo.


Clinical Study Identifier: s21-01255
ClinicalTrials.gov Identifier: NCT04981717
Principal Investigator: Anna H Nowak-Wegrzyn.
Other Investigator: Amanda Schneider.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.